Source:http://linkedlifedata.com/resource/pubmed/id/21148082
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2011-2-11
|
| pubmed:databankReference | |
| pubmed:abstractText |
The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been associated with short remission duration and extramedullary relapse. We investigated the clinical significance of CD56 expression in a large series of patients with APL treated with all-trans retinoic acid and anthracycline-based regimens. Between 1996 and 2009, 651 APL patients with available data on CD56 expression were included in 3 subsequent trials (PETHEMA LPA96 and LPA99 and PETHEMA/HOVON LPA2005). Seventy-two patients (11%) were CD56(+) (expression of CD56 in ? 20% leukemic promyelocytes). CD56(+) APL was significantly associated with high white blood cell counts; low albumin levels; BCR3 isoform; and the coexpression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. For CD56(+) APL, the 5-year relapse rate was 22%, compared with a 10% relapse rate for CD56(-) APL (P = .006). In the multivariate analysis, CD56 expression retained the statistical significance together with the relapse-risk score. CD56(+) APL also showed a greater risk of extramedullary relapse (P < .001). In summary, CD56 expression is associated with the coexpression of immaturity-associated and T-cell antigens and is an independent adverse prognostic factor for relapse in patients with APL treated with all-trans-retinoic acid plus idarubicin-derived regimens. This marker may be considered for implementing risk-adapted therapeutic strategies in APL. The LPA2005 trial is registered at http://www.clinicaltrials.gov as NCT00408278.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:BerguaJuanJ,
pubmed-author:BrunetSalutS,
pubmed-author:BuenoJavierJ,
pubmed-author:EscodaLourdesL,
pubmed-author:EsteveJordiJ,
pubmed-author:GonzálezJosé DJD,
pubmed-author:GonzálezJoséJ,
pubmed-author:GonzálezMarcosM,
pubmed-author:HOVON Groups,
pubmed-author:HolowieckaAleksandraA,
pubmed-author:KrsnikIsabelI,
pubmed-author:LowenbergBobB,
pubmed-author:MansoFélixF,
pubmed-author:MiloneGustavoG,
pubmed-author:MontesinosPauP,
pubmed-author:Pérez-EncinasManuelM,
pubmed-author:PérezInmaculadaI,
pubmed-author:PETHEMA,
pubmed-author:RayónCheloC,
pubmed-author:RiberaJosep MJM,
pubmed-author:RivasConchaC,
pubmed-author:RubioVicenteV,
pubmed-author:SanzMiguel AMA,
pubmed-author:TormoMarM,
pubmed-author:VellengaEdoE,
pubmed-author:de la SernaJavierJ
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
10
|
| pubmed:volume |
117
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1799-805
|
| pubmed:meshHeading |
pubmed-meshheading:21148082-Adolescent,
pubmed-meshheading:21148082-Adult,
pubmed-meshheading:21148082-Anthracyclines,
pubmed-meshheading:21148082-Antigens, CD56,
pubmed-meshheading:21148082-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21148082-Female,
pubmed-meshheading:21148082-Humans,
pubmed-meshheading:21148082-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:21148082-Male,
pubmed-meshheading:21148082-Middle Aged,
pubmed-meshheading:21148082-Prognosis,
pubmed-meshheading:21148082-Recurrence,
pubmed-meshheading:21148082-Risk Factors,
pubmed-meshheading:21148082-Tretinoin,
pubmed-meshheading:21148082-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
|
| pubmed:affiliation |
Hospital Universitario La Fe, Valencia, Spain.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|